Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
Isha Kapoor(Central Drug Research Institute), Alexandru Almasan(Cleveland Clinic Lerner College of Medicine)
Cited by 76
Related Papers
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
|Cell Death and Disease|2015|378
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
|Cell Death and Disease|2020|257
Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
|Molecular Cancer|2014|71